Article

Variables in models can provide invaluable insights to disease

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

Dr. Ambati defended animal models of age-related macular degeneration despite differences in eye structure and disease development between humans and other species often used in testing, such as primates, mice, and rabbits.

"Even imperfect models can provide invaluable insights," he said.

The validity of an animal model can be measured by several variables: face validity, or how well it copies the human condition; whether it obeys the genetic aspects of the disease; and how well it parallels the immunologic and pathogenetic mechanisms.

"This betrays the clinician's bias, but what is most important is how well it tells us something we didn't already know," Dr. Ambati said. "What does it predict, either about mechanisms or about treatment or diagnosis? Does it ultimately reveal some novel insights?"

He added that there is no single best choice of a model but that ongoing dialogue between basic scientists and clinical investigators will continue to lead to new discoveries.

He added that although mice lack maculas, several important insights have been gained from mouse models recently on issues such as development of choroidal neovascularization via substances found in drusen.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.